Hospital program for fatty liver disease
Part of Digestive system, Hormones & metabolism clinical trials.
This study tests whether a hospital program can help people with fatty liver disease. It may be a good fit if you have mild to moderate liver scarring and are not a heavy drinker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with fatty liver (hepatic steatosis).
- Your diagnosis was confirmed by an ultrasound or CT scan.
- You have mild to moderate liver scarring (fibrosis stage F1 to F3) or a FIB-4 score less than 3.5.
- You are not a heavy drinker (more than 5 drinks per week for women, 7 for men).
- You do not have another liver condition that needs separate care.
- You are willing to sign a consent form to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
This study asks people with metabolic fatty liver disease and liver scarring about their experiences. It aims to learn what matters to you so doctors can improve care.
This study looks at how the liver's immune environment changes in people with non-alcoholic fatty liver disease (NAFLD) that has progressed to significant scarring. Researchers will use a liver biopsy to understand the inflammation better, which may lead to new treatments.
This study tests whether a specially designed gut bacteria treatment can help people with fatty liver disease and related health issues like high blood sugar, high cholesterol, or high blood pressure. It aims to see if the treatment is safe and improves liver health.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This study tests a way to find liver scarring (fibrosis) early in people who have risk factors like being overweight, having type 2 diabetes, or drinking alcohol heavily. Early detection may help prevent serious liver damage.
Hear when a new Hepatic Steatosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.